Log in

NYSE:GENGenesis Healthcare Stock Price, Forecast & News

+0.27 (+35.06 %)
(As of 05/22/2020 04:00 PM ET)
Today's Range
Now: $1.04
50-Day Range
MA: $0.77
52-Week Range
Now: $1.04
Volume6.47 million shs
Average Volume642,995 shs
Market Capitalization$171.40 million
P/E RatioN/A
Dividend YieldN/A
Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services, Rehabilitation Therapy Services, and All Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of December 31, 2018, it provided inpatient services through a network of 425 skilled nursing and assisted/senior living facilities, including 399 skilled nursing facilities and 26 stand-alone assisted/senior living facilities across 29 states. Genesis HealthCare, Inc. also supplies rehabilitation and respiratory therapy to approximately 1,400 healthcare locations in 46 states and the District of Columbia. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.
Read More
Genesis Healthcare logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.74 out of 5 stars

Industry, Sector and Symbol

Industry Skilled nursing care facilities



Sales & Book Value

Annual Sales$4.57 billion
Cash Flow$0.84 per share
Book Value($6.57) per share


Net Income$14.62 million


Market Cap$171.40 million
Next Earnings Date5/27/2020 (Confirmed)

Receive GEN News and Ratings via Email

Sign-up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter.

Genesis Healthcare (NYSE:GEN) Frequently Asked Questions

How has Genesis Healthcare's stock been impacted by COVID-19 (Coronavirus)?

Genesis Healthcare's stock was trading at $1.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GEN shares have decreased by 10.3% and is now trading at $1.04. View which stocks have been most impacted by Coronavirus.

When is Genesis Healthcare's next earnings date?

Genesis Healthcare is scheduled to release its next quarterly earnings announcement on Wednesday, May 27th 2020. View our earnings forecast for Genesis Healthcare.

How can I listen to Genesis Healthcare's earnings call?

Genesis Healthcare will be holding an earnings conference call on Wednesday, May 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Genesis Healthcare's earnings last quarter?

Genesis Healthcare Inc (NYSE:GEN) released its earnings results on Monday, March, 16th. The company reported ($0.10) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.01. The company earned $1.14 billion during the quarter. Genesis Healthcare had a net margin of 0.32% and a negative return on equity of 1.33%. During the same quarter in the prior year, the business earned ($0.67) EPS. View Genesis Healthcare's earnings history.

Has Genesis Healthcare been receiving favorable news coverage?

News coverage about GEN stock has trended somewhat negative on Sunday, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genesis Healthcare earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutGenesis Healthcare.

Are investors shorting Genesis Healthcare?

Genesis Healthcare saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,300,000 shares, an increase of 8.0% from the April 30th total of 2,130,000 shares. Based on an average trading volume of 393,000 shares, the short-interest ratio is currently 5.9 days. Currently, 4.2% of the company's stock are sold short. View Genesis Healthcare's Current Options Chain.

Who are some of Genesis Healthcare's key competitors?

What other stocks do shareholders of Genesis Healthcare own?

Who are Genesis Healthcare's key executives?

Genesis Healthcare's management team includes the following people:
  • Mr. George V. Hager Jr., CEO & Director (Age 63)
  • Mr. Thomas DiVittorio, CFO, Exec. VP, Treasurer & Assistant Sec. (Age 51)
  • Mr. Paul David Bach, COO & Exec. VP (Age 60)
  • Dr. JoAnne Susan Reifsnyder Ph.D., MSN, MBA, FAAN, Exec. VP of Clinical Operations & Chief Nursing Officer (Age 60)
  • Mr. Richard L. Castor, Chief Information Officer & Sr. VP (Age 64)

What is Genesis Healthcare's stock symbol?

Genesis Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "GEN."

Who are Genesis Healthcare's major shareholders?

Genesis Healthcare's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (2.74%), First Washington CORP (2.18%), Acadian Asset Management LLC (0.99%), State Street Corp (0.79%), Geode Capital Management LLC (0.48%) and Nuveen Asset Management LLC (0.35%). Company insiders that own Genesis Healthcare stock include David A Reis, George V Hager, Jr, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young and Thomas Divittorio. View institutional ownership trends for Genesis Healthcare.

Which major investors are selling Genesis Healthcare stock?

GEN stock was sold by a variety of institutional investors in the last quarter, including First Washington CORP, BlackRock Inc., JPMorgan Chase & Co., UBS Group AG, and Nuveen Asset Management LLC. Company insiders that have sold Genesis Healthcare company stock in the last year include George V Hager, Jr, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young, and Thomas Divittorio. View insider buying and selling activity for Genesis Healthcare.

Which major investors are buying Genesis Healthcare stock?

GEN stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, State Street Corp, SG Americas Securities LLC, Connor Clark & Lunn Investment Management Ltd., Wells Fargo & Company MN, and Acadian Asset Management LLC. View insider buying and selling activity for Genesis Healthcare.

How do I buy shares of Genesis Healthcare?

Shares of GEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genesis Healthcare's stock price today?

One share of GEN stock can currently be purchased for approximately $1.04.

How big of a company is Genesis Healthcare?

Genesis Healthcare has a market capitalization of $171.40 million and generates $4.57 billion in revenue each year. The company earns $14.62 million in net income (profit) each year or $0.10 on an earnings per share basis. Genesis Healthcare employs 55,000 workers across the globe.

What is Genesis Healthcare's official website?

The official website for Genesis Healthcare is www.genesishcc.com.

How can I contact Genesis Healthcare?

Genesis Healthcare's mailing address is 101 EAST STATE STREET, KENNETT SQUARE PA, 19348. The company can be reached via phone at 610-444-6350 or via email at [email protected]

This page was last updated on 5/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.